In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adaptive Licensing: Industry On Board, With Caveats

Executive Summary

The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.

You may also be interested in...



EMA Ready To End Adaptive Pathways Pilot, Tap Into Lessons Learned

"Successful" pilot project supports integrating concepts into existing regulatory frameworks, EMA official who coordinated it says.

'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context

EMA official gives perspectives on how PRIME and adaptive pathways compare, and how they fit with other programs such as conditional authorization.

EMA Head On Transparency, Affordable Innovation, And What Patients Really Need

EMA will reinforce its role as a global reference authority and help build regulatory capacity in less experienced countries, Guido Rasi says in outlining his five-year priorities for the agency. He hopes regulatory efficiencies might contribute to lower drug prices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel